PT-141 research: the RECONNECT measurements
The central clinical question is how much the women’s lives improved. The trial scores supply a measured answer, with a separate conversation still needed about its importance.
The RECONNECT trials
The two randomized Phase 3 RECONNECT trials enrolled 1,267 premenopausal women with acquired, generalized HSDD. Studies 301 and 302 compared bremelanotide with placebo over 24 weeks. The active-treatment group received 1.75 mg subcutaneously as needed; this is the study’s treatment figure.
The trials used questionnaires to measure both sexual desire and distress about low desire. Across the integrated results, the FSFI desire-domain difference versus placebo was +0.35. The FSDS-DAO item 13 difference was -0.33; that item asks about distress associated with low desire. Both comparisons had P<.001. The results met the coprimary endpoints in both trials.
I give the replication across the trial pair credit. Equally, those decimal changes resist a grand description of restored sexuality. They describe modest average differences on particular questionnaire measures. The debate about how much that helps in everyday life survives the statistical result.
Questionnaire outcomes
The RECONNECT report measures wanting sex and distress about its loss. Putting those outcomes beside one another matters to me: a change in desire has a different significance when the person herself is troubled by the loss.
For me, those small group differences call for restrained language, with room for a woman to value the change differently from someone else. Calling the effect small says something about the group comparison. It gives no permission to dismiss the distress that brought women into the studies, nor to assume a dramatic improvement for an individual.
The question I’d bring back to a clinical conversation is practical: which change would make treatment worth continuing? The side-effect findings make that question especially relevant.
Following 684 women for 52 weeks
The open-label extension enrolled 684 women and followed treatment for up to 52 weeks. Desire improvements were sustained and no new safety signals emerged. Nausea was the leading tolerability problem; flushing and headache followed among the common drug-related adverse events.
Open-label means participants knew they were receiving the medicine. The extension also lacked a placebo group, so its account of continued improvement has less control over alternative explanations than the randomized trials. I’m more comfortable using it to discuss the experience of continuing treatment than to announce a fresh, equally strong proof of efficacy.
The longer-treatment side-effect figures come from this extension. They describe its women and its follow-up period.
The small imaging study
The crossover experiment in 31 women adds a mechanistic angle: altered brain processing of erotic stimuli and increased reported desire for up to 24 hours. Its size and purpose differ from RECONNECT. I welcome the chance to connect brain activity with reported experience, and still want the clinical question answered in the terms a person lives with.
The mechanism page follows that experiment alongside the animal work. In particular, the female Syrian hamster reward result complicates an easy equation between seeking sex and finding it more rewarding.
Appetite
In two randomized Phase 1 trials in obese premenopausal women, investigators used frequent experimental treatment to examine body weight and food intake. Study A found -1.3 kg versus placebo over 16 days, with p<.0001; caloric intake fell by approximately 400 kcal/day.
Those precise figures make the appetite role of MC4R tangible. They also came from a different research question and experimental regimen. Bremelanotide has no approval for weight-loss treatment. I see these results as a reminder to ask about effects beyond the one named in a treatment discussion.
Men and later reviews
The early pharmacology report included erectile responses in men. The 2004 development profile describes the nasal-spray program before the later focus on an approved injection for women. The prescribing information limits approval to premenopausal HSDD, leaving men and postmenopausal women outside that indication.
A 2025 review of pharmacologic treatments for female sexual dysfunction, another 2025 review of vasomotor and sexual symptoms, and the 2026 multidisciplinary HSDD recommendations discuss treatment in a broader clinical setting. Their roles are synthesis and guidance. The original trials remain the place to inspect the women, the measurements and the size of the changes reported here.